SCHEMBL20255669

SCHEMBL20255669

N#Cc1cccc(-c2cc(Cl)ccc2OS(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.60
PDE4A P27815 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
BACE1 P56817 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
EPAS1 Q99814 2/20 0.40
MRGPRX4 Q96LA9 1/20 0.40
VEGFA P15692 1/20 0.39
EIF4EBP1 Q13541 2/20 0.39
ENPP1 P22413 1/20 0.39
SCN9A Q15858 1/20 0.38
PTPN5 P54829 1/20 0.38
RORC P51449 1/20 0.37
ACLY P53396 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5093150 0.86 PDE4D (0.48) PTGDR2PDE4APDE4CPDE4DMEN1
SCHEMBL17410657 0.83 PTGDR2 (0.51) PTGDR2PDE4APDE4CPDE4DBACE1
SCHEMBL2112925 0.77 PTGDR2 (0.63) PTGDR2PDE4DBACE1MAPTMRGPRX4
SCHEMBL20241823 0.76 PTGDR2 (0.41) PTGDR2PDE4APDE4CPDE4DEPAS1
SCHEMBL7112370 0.76 PDE4A (0.48) PDE4APDE4CPDE4DMEN1MAPT
SCHEMBL30163443 0.76 PTGDR2 (0.41) PTGDR2PDE4APDE4CPDE4DEPAS1
SCHEMBL3363775 0.75 AR (0.44) PDE4APDE4CPDE4DEPAS1MRGPRX4
SCHEMBL1690361 0.75 PTGDR2 (1.00) PTGDR2EIF4EBP1
SCHEMBL1754952 0.75 PTGDR2 (0.67) PTGDR2MEN1LMNAMAPTHTT
SCHEMBL30163385 0.75 PTGDR2 (0.43) PTGDR2PDE4APDE4CPDE4DKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230061841-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-03-02 US disclosed
US-11091451-B2 SHMT inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-08-17 US disclosed
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-11-14 US disclosed
WO-2018106636-A1 SHMT INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2018-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091451-B2 SHMT inhibitors and uses thereof SHMT1, SHMT2, BHMT PTGDR2 4109/4885PDE4A 3223/4885PDE4C 3425/4885
US-20230061841-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT PTGDR2 4109/4885PDE4A 3223/4885PDE4C 3425/4885
US-20190345119-A1 SHMT INHIBITORS AND USES THEREOF SHMT1, SHMT2, BHMT PTGDR2 4109/4885PDE4A 3223/4885PDE4C 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.